
Please try another search
On Tuesday, UBS expressed a positive outlook on Dr Lal PathLabs Ltd (DLPL:IN), with a revised price target of INR3,500, up from INR2,900, while retaining a Buy rating on the stock. The firm's stance...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review